What Factors Affect Lamotrigine Dosage?

Lamotrigine dispersible tablets, epilepsy: monotherapy for children over 12 years and adults: 1. simple partial seizures 2. complex partial seizures 3. secondary generalized tonic-clonic seizures 4. Tonic clonic seizures. Monotherapy is not currently recommended for children under 12 years of age, as data for controlled trials in this special population are not available. Additive therapy for children over 2 years and adults: 1. Simple partial seizures. 2. Complex partial seizures. 3 Secondary systemic tonicity with clonic seizures. 4 Primary systemic tonicity with clonic seizures. This product can also treat seizures with Lennox-Gastaut syndrome. ^[1] .

Lamotrigine dispersible tablets, epilepsy: monotherapy for children over 12 years of age and adults: 1. simple partial seizures 2. complex partial seizures 3. secondary systemic tonic-clonic seizures 4. primary systemic Tonic clonic seizures. Monotherapy is not currently recommended for children under 12 years of age, as data for controlled trials in this special population are not available. Additive therapy for children over 2 years and adults: 1. Simple partial seizures. 2. Complex partial seizures. 3 Secondary systemic tonicity with clonic seizures. 4 Primary systemic tonicity with clonic seizures. This product can also treat seizures with Lennox-Gastaut syndrome. ^[1] .

Drug Name

Lamotrigine Dispersible Tablets

Use classification

Sodium channel regulators

Lamotrigine Dispersible Tablets Ingredients

The main ingredient of this product is lamotrigine. Its chemical name is: 3,5 diamino 5-6- (2,3-dichlorophenyl) -1,2,4-triazine.
Molecular formula: C ₉ H ₇ C ₁₂ N ₅
Molecular weight: 256.09

Lamotrigine Dispersible Tablets

This product is white or nearly white round, flat uncoated tablet.

Lamotrigine dispersible tablets indications

Epilepsy: Monotherapy for children over 12 years of age and adults: 1. Simple partial seizures 2. Complex partial seizures 3. Secondary generalized tonic-clonic seizures 4. Primary primary tonic-clonic seizures. Monotherapy is not currently recommended for children under 12 years of age, as data for controlled trials in this special population are not available. Additive therapy for children over 2 years and adults: 1. Simple partial seizures. 2. Complex partial seizures. 3 Secondary systemic tonicity with clonic seizures. 4 Primary systemic tonicity with clonic seizures. This product can also treat seizures with Lennox-Gastaut syndrome.

Lamotrigine Dispersible Tablets Specifications

50mg

Lamotrigine dispersible tablets

It can be taken orally, chewed or swallowed directly, or taken with a small amount of water. To ensure that the therapeutic dose is maintained, the patient's weight should be monitored and the dose should be checked when the weight changes. When other combined anti-epileptic drugs are discontinued and treated with this product alone or other anti-epileptic drugs are added to the additive treatment plan of this product, the effect of the above changes on the pharmacokinetics of lamotrigine (see [Drugs interaction). Monotherapy dose: Adults and children over 12 years old: The initial dose of monotherapy for this product is 25 mg once daily for two weeks; then 50 mg once daily for two weeks. Thereafter, the dose was increased every 2 weeks, with a maximum increase of 50-100 mg, until the best effect was achieved. The maintenance dose that usually achieves the best effect is 100-200mg / day, which is administered once or twice daily. However, some patients need to take 500mg of lamotrigine daily to achieve the desired effect.

Lamotrigine dispersible tablets adverse reactions

In trials of this drug as a monotherapy, adverse reactions have been reported including headache, fatigue, rash, nausea, dizziness, lethargy and insomnia. In clinical double-blind, additive trials, the incidence of rash was as high as 10% in patients taking lamotrigine and 5% in patients taking placebo. 2% of patients discontinued lamotrigine due to a rash. This rash is usually maculopapular in appearance and usually appears 8 weeks before the start of treatment. It disappears after lamotrigine is stopped. Rare, severe rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell syndrome), have been reported, and rare cases have been associated with death. The overall risk of rash is closely related to the following factors: the initial dose of lamotrigine is too large and the lamotrigine treatment upgrade exceeds the recommended dose; at the same time, the use of valproate sodium can increase the average half-life of lamotrigine close to 2 Times. It has also been reported that the rash is part of an allergic syndrome and is accompanied by many forms of systemic symptoms, including fever, lymphadenopathy, facial edema, and abnormalities in blood and liver. The severity of the clinical response to this syndrome varies widely. Rare diffuse intravascular coagulation (DIC) and multiple organ failure. Even if the rash is not obvious, it is important to pay attention to early manifestations of allergic reactions (eg fever, lymphadenopathy). If signs and symptoms of early reactions appear, the patient should be evaluated immediately; if no other cause can be determined, the drug should be discontinued. When lamotrigine is added to the standard antiepileptic regimen, other adverse reactions include diplopia, blurred vision, conjunctivitis, dizziness, drowsiness, headache, fatigue, gastrointestinal disorders (including vomiting and diarrhea), and irritability / Aggression, ataxia, anxiety, confusion, and hematological abnormalities (including leukopenia and thrombocytopenia).

Lamotrigine dispersible tablets contraindications

It is contraindicated in patients who are allergic to lamotrigine and any ingredients in this product.

Lamotrigine dispersible tablets

Adverse skin reactions have been reported and generally occur 8 weeks before the start of lamotrigine treatment. Most rashes are mild and self-limiting; however, severe, fatal and dangerous rashes have been rare, including reports of Stevens-Johnson syndrome and toxic epithelial necrosis. The incidence of severe rash is about 1: 1000 in adults, and it is higher in children under 12 than in adults. Studies have shown that the rate of adverse reactions requiring hospitalization among children under 12 years of age is 1: 300-1: 100. In children, the initial rash may be mistaken for an infection; in the first 8 weeks of treatment with this drug, if the child develops symptoms of rash and fever, the possibility of a drug reaction should be considered. In addition, the overall risk of rash is related to the following factors: the initial dose of lamotrigine is too high and the subsequent increase in dose exceeds the recommended dose; the simultaneous use of valproate: it increases the average half-life of lamotrigine About 2 times. All patients (adults and children) who develop a rash should be evaluated promptly and lamotrigine be discontinued immediately unless a rash can be diagnosed that is not related to this drug. It has also been reported that rash is part of an allergic syndrome with many forms of systemic symptoms, including fever, lymphadenopathy, facial edema, and abnormalities in blood and liver. The severity of the clinical response caused by this syndrome is wide; diffuse diffuse intravascular coagulation and multiple organ failure are rare. Even if the rash is not obvious, it is important to note the early manifestations of allergic reactions (ie fever, lymphadenopathy). If such signs and symptoms appear, the patient should be evaluated immediately; if another cause cannot be determined, the drug should be discontinued. When co-administered with other antiepileptic drugs, sudden discontinuation of this drug can cause seizures. Unless sudden withdrawal is required due to safety considerations (such as a rash), the dose of this medicine should be gradually reduced to within 2 weeks. When you want to stop using other combined antiepileptic drugs in order to achieve the monotherapy of this drug, or add other antiepileptic drugs to this drug, the effects on the pharmacokinetics of lamotrigine should be considered. This medicine is a weak inhibitor of dihydrofolate reductase. Long-term treatment may interfere with folate metabolism. However, after long-term administration in humans for up to one year, lamotrigine has not caused significant changes in hemoglobin concentration, average red blood cell capacity, and folate concentration in serum or red blood cells; it has no significant effect on red cell folate concentration for up to five years. . In single-dose studies of patients with advanced renal failure, the plasma lamotrigine concentration did not change significantly, however, accumulation of glucuronic acid metabolites can be expected; therefore, care should be taken in patients with renal failure. This medicine is mainly cleared by liver metabolism. The use of this drug in patients with severely impaired liver function has not been studied. Until such information is available, this patient is not recommended for this drug. It has been reported in the literature that severe seizures, including status epilepticus, can lead to rhabdomyolysis, multiple organ dysfunction, and diffuse intravascular coagulation, which can sometimes be fatal. Similar situations have occurred with the use of this drug. However, the relationship between lamotrigine and the above reactions has not yet been established.

Lamotrigine dispersible tablets for pregnant and lactating women

As directed by your doctor.

Lamotrigine dispersible tablets for children

As directed by your doctor.

Lamotrigine dispersible tablets for elderly

As directed by your doctor.

Lamotrigine dispersible tablets drug interactions

Studies have shown that ethinyl estradiol / levonorgestrel (30mcg / 150mcg) mixture can increase the clearance of lamotrigine by about two times, leading to a decrease in lamotrigine levels.

Lamotrigine Dispersible Tablets Pharmacology and Toxicology

The results of pharmacological studies suggest that lamotrigine is a voltage-dependent sodium channel blocker. In cultured nerve cells, it repeatedly discharges and inhibits the pathological release of glutamate (a type of amino acid that plays a key role in the formation of seizures). It also suppresses the glutamate-induced action potential burst. In a trial designed to evaluate the effect of the drug on the central nervous system, healthy volunteers took 240 mg of lamotrigine and the results were no different from placebo; however, 1000 mg of phenytoin and 10 mg of diazepam significantly impaired subtle visual movement The coordination and eye movements increase and produce subjective sedative effects. In another study, a single 600 mg oral carbamazepine significantly impaired the coordination of subtle visual movements and eye movements, at which time both body swing and heart rate increased; however, 150 and 300 mg of lamo For triazine, the results were no different from placebo. See the inner package manual for details.

Lamotrigine Dispersible Tablets Storage

Protect from light and sealed.

Lamotrigine Dispersible Tablets Packaging

Packed in aluminum-plastic blister, 50mg * 56s / box.

Lamotrigine Dispersible Tablets

36 months

Lamotrigine Dispersible Tablets

JX20110018